Therapeutic composition containing antibodies to soluble polypeptide fractions of LAG-3 protein
AssigneesInstitut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale, Applied Research Systems ARS Holding N.V.
InventorsFlorence Faure, Thierry Hercend, Bertrand Huard, Frederic Triebel
Life of this patent
Estimating the term…
Abstract
Soluble polypeptide fraction consisting of all or part of one at least one of the four immunoglobulin-type extracellular LAG-3 protein domains (amino acids 1-159, 160-230, 240-330 and 331-412 of the SEQ ID NO:1 sequence) or consisting of one peptide sequence derived from these domains by replacement, addition or deletion of one or more amino acids. The fraction of the invention has a specificity at least equal to that of LAG-3 in relation to its ligand.
Claims5
A composition comprising an antibody G.sub.1 raised against an antigen selected from the group consisting of:
- LAG-3 (SEQ ID NO:1);
- soluble polypeptide fractions consisting of at least one of the four immunoglobulin type extracellular domains of the LAG-3 protein (amino acids 1-149, 150-239, 240-330 and 331-412 of SEQ ID NO:1);
- and a substituted LAG-3 or a substituted immunoglobulin type extracellular domain of LAG-3 consisting of amino acid residues 1-149, where one or more arginine residues at residue positions 73, 74 and 76 of SEQ ID NO:1 are substituted with glutamic acid residues.
A method of stimulating the immune system comprising administering to a subject in need of such treatment an immunostimulatory amount of an antibody raised against an antigen selected from the group consisting of:
- LAG-3;
- soluble polypeptide fractions consisting of at least one of the four immunoglobulin type extracellular domains of the LAG-3 protein (amino acids 1-149, 150-239, 240-330 and 331-412 of SEQ ID NO:1), a substituted LAG-3 or a substituted immunoglobulin type extracellular domain of LAG-3 consisting of amino acid residues 1-149, where one or more arginine residues at residue positions 73, 75 and 76 of SEQ ID NO:1 are substituted with glutamic acid residues.
Dependencies are inferred from the claim text.